Back

REDUCE-IT: accumulation of data across prespecified interim analyses to final results

30 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Non-statin Treatment of Dyslipidemia Drug therapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Brian Olshansky

VETERANS HEALTH ADMINISTRATION, Iowa City (United States of America)

7 More presentations in this session

Presentation thumbnail
Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study
Ms J. Pavlovic (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.
Doctor L. Lobo (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
Are the results of clinical trials relevant in the real world? The applicability of REDUCE-IT to the FAST-MI Registry.
Professor J. Ferrieres (Toulouse, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Non-statin Treatment of Dyslipidemia

The Event

Event poster

ESC Congress 2020

30 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020
thumbnail
Congress Presentation
Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial
27 August 2021
thumbnail
Congress Presentation
Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome
2 September 2024
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
19 February 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources